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AJOG at a Glance:  37 
Why was this study conducted? 38 
• To perform a systematic review and meta-analysis to evaluate the effect of low-39 
dose aspirin initiated at <11 weeks’ gestation on the risk of preeclampsia, 40 
gestational hypertension, or any hypertensive disorder of pregnancy. 41 
Secondary outcomes included preterm delivery at <37 weeks’ gestation and 42 
fetal growth restriction.  43 
Key findings  44 
• The administration of low-dose aspirin at <11 weeks’ gestation in women with 45 
a history of recurrent pregnancy loss, women who had undergone in vitro 46 
fertilization or women with thrombophilia or antiphospholipid syndrome was 47 
associated with a non-significant decrease in the risk of preeclampsia, 48 
gestational hypertension, and any hypertensive disorder of pregnancy.  49 
• Early low-dose aspirin reduced the risk of preterm delivery but had no impact 50 
on the risk of fetal growth restriction.  51 
• Except for preterm delivery and any hypertensive disorder of pregnancy, 52 
sensitivity analysis demonstrated similar observations; confirming the 53 
robustness of our analysis. 54 
What does this add to what is known? 55 
• Administration of low-dose aspirin at <11 weeks’ gestation to high risk women 56 
does not reduce the risk of preeclampsia, gestational hypertension, any 57 
hypertensive disorder of pregnancy and fetal growth restriction but might 58 






OBJECTIVE DATA: Pre-conception or early administration of low-dose aspirin might 63 
improve endometrial growth, placental vascularization and organogenesis. Most 64 
studies have evaluated the potential benefit of pre-conception or early administration 65 
of low-dose aspirin in women with a history of recurrent pregnancy loss, women who 66 
have undergone in vitro fertilization or women with thrombophilia or antiphospholipid 67 
syndrome. These women are at an increased risk of placenta-associated 68 
complications of pregnancy, including preeclampsia, preterm delivery and fetal growth 69 
restriction. 70 
STUDY: We performed a systematic review and meta-analysis to evaluate the effect 71 
of low-dose aspirin initiated at <11 weeks’ gestation on the risk of preeclampsia, 72 
gestational hypertension, or any hypertensive disorder of pregnancy. Secondary 73 
outcomes included preterm delivery at <37 weeks’ gestation and fetal growth 74 
restriction. 75 
STUDY APPRAISAL AND SYNTHESIS METHODS: We searched in MEDLINE via 76 
PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), 77 
ClinicalTrials.Gov and the World Health Organization International Clinical Trials 78 
Registry Platform (WHO-ICTRP) from 1985 to November 2018.  Entry criteria were 79 
randomized controlled trials evaluating the effect of aspirin administered at <11 weeks’ 80 
gestation in preventing preeclampsia and/or hypertensive disorders in pregnancy or 81 
improving pregnancy outcomes in women with recurrent miscarriage as compared to 82 
placebo or no-treatment and outcome data available or provided by authors for >85% 83 
of the study population. Relative risks (RR) with 95% confidence intervals (CI) were 84 
calculated for each study and pooled for global analysis as the effect measure. We 85 
assessed statistical heterogeneity in each meta‐analysis using the Chi² statistics, I² 86 
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and Tau². Heterogeneity was considered substantial if an I² was greater than 50% and 87 
either the Tau² was greater than zero, or there was a low P-value (<0.10) in the Chi² 88 
test for heterogeneity. Random‐effects meta‐analysis, weighted by the size of the 89 
studies, was performed to produce an overall summary on aspirin effect for each 90 
outcome. Sensitivity analysis by sequential omission of each individual study and by 91 
fixed-effects model was performed. Publication bias was not assessed due to the small 92 
number of included studies. Statistical analysis was performed using Stata release 93 
14.0 (StataCorp, College Station, TX).  94 
RESULTS: The entry criteria were fulfilled by eight randomized controlled trials on a 95 
combined total of 1,426 participants. Low-dose aspirin initiated at <11 weeks’ 96 
gestation was associated with a non-significant reduction in the risk of preeclampsia 97 
(RR 0.52; 95% CI: 0.23-1.17, P=0.115), gestational hypertension (RR 0.49; 95% CI: 98 
0.20-1.21; P=0.121) and any hypertensive disorder of pregnancy (RR 0.59; 95% CI 99 
0.33-1.04, P=0.067). Early low-dose aspirin reduced the risk of preterm delivery (RR 100 
0.52; 95% CI: 0.27-0.97, p=0.040) but had no impact on the risk of fetal growth 101 
restriction (RR 1.10; 95% CI 0.58-2.07, P=0.775). Except for preterm delivery and any 102 
hypertensive disorder of pregnancy, sensitivity analysis demonstrated similar 103 
observations; therefore confirming the robustness of the analysis.  104 
CONCLUSION: The administration of low-dose aspirin at <11 weeks’ gestation in high 105 
risk women does not decrease the risk of preeclampsia, gestational hypertension, any 106 
hypertensive disorder of pregnancy and fetal growth restriction. However, it might 107 
reduce the risk of preterm delivery. Larger randomized controlled trials will be required 108 
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Aspirin, also known as acetylsalicylic acid, is the most widely used medication with 50 121 
to 120 billion pills consumed each year.(1) Aspirin was first discovered over 3,500 years 122 
ago - its analgesic effect was described when willow leaves were used to treat 123 
inflammatory rheumatic diseases.(2) In 1828, Joseph Bucher extracted the active 124 
ingredient from the willow bark and it was named as “salicin”.(3) The purest and most 125 
stable form of acetylsalicylic acid was obtained on 10 August 1897 and, since then 126 
this medication has gained therapeutic success worldwide. Thus far, aspirin is 127 
recommended for the primary and secondary prevention of cardiovascular disease,(4-128 
6) as well as several cancers such as colorectal, gastro-esophageal, breast and 129 
prostate.(7, 8)  130 
 131 
In obstetrics, low-dose aspirin has been shown to be effective in preventing preterm 132 
preeclampsia, with delivery at <37 weeks’ gestation, in women at risk.(9-26) The ASPRE 133 
(Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for 134 
Evidence‐Based Preeclampsia Prevention) trial demonstrated that in high risk 135 
women, identified by the first-trimester combined test, who were randomized to 136 
receive aspirin (150 mg per night) vs. placebo from 11-14 until 36 weeks’ gestation, 137 
the rate of preterm preeclampsia was substantially reduced (aspirin: 1.6% [13/798] vs. 138 
placebo: 4.3% [35/822]; odds ratio [OR] 0.38, 95% confidence intervals [CI], 0.20-139 
0.74).(27) The latest systematic review and meta-analysis demonstrated that the 140 
reduction in the rate of preterm preeclampsia was confined to the subgroup in which 141 
aspirin was initiated at ≤16 weeks’ gestation and at a daily dose of ≥100 mg (relative 142 




Evidence suggests that pre-conception or early administration of low-dose aspirin 145 
might improve endometrial growth, placental vascularization and organogenesis.(17, 28-146 
36)  Following the success of the ASPRE trial, the question that remains is whether 147 
high risk women should start low-dose aspirin before pregnancy or during the very 148 
early stage of pregnancy. To date, most studies have evaluated the potential benefit 149 
of pre-conception or early administration of low-dose aspirin in women with a history 150 
of recurrent pregnancy loss,(37-40) women who have undergone in vitro fertilization 151 
(IVF)(28, 41-54) or women with thrombophilia or antiphospholipid syndrome.(55-65) It is 152 
recognized that these women are at an increased risk of placenta-associated 153 
complications of pregnancy, including hypertensive disorder of pregnancy,(66-69) 154 
preterm delivery,(70, 71) and fetal growth restriction.(70, 72) 155 
 156 
The objective of this study was to perform a systematic review and meta-analysis to 157 
estimate the effect of low-dose aspirin initiated at <11 weeks’ gestation on the risk of 158 
preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy. 159 
 160 
MATERIALS AND METHODS 161 
 162 
Type of studies 163 
This is a systematic review and meta-analysis of randomized controlled trials including 164 
studies that recruited women for the prevention of preeclampsia with the use of aspirin 165 
commenced at <11 weeks’ gestation. Treatment includes aspirin compared with 166 
placebo or no-treatment. We did not include cross-over trials or studies of 167 
observational designs such as case-control studies or cohort studies in this meta-168 
8 
 
analysis but we considered such evidence in the discussion, where relevant. Studies 169 
were excluded if pregnant women started treatment at or after 11 weeks’ gestation or 170 
there was no placebo or no-treatment group.  171 
 172 
Research strategy 173 
In clinical practice, pre-conception or very early aspirin administration is advised for 174 
women with recurrent miscarriage.(73) Therefore, we have included the terms recurrent 175 
abortion and habitual abortion in the keywords. Keywords and MeSH terms (aspirin, 176 
preeclampsia, recurrent abortion, habitual abortion) related to aspirin commenced at 177 
<11 weeks’ gestation for preeclampsia prevention were searched in MEDLINE via 178 
PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), 179 
ClinicalTrials.Gov and World Health Organization International Clinical Trials Registry 180 
Platform (WHO-ICTRP) from 1985 to November 2018. No language restrictions were 181 
applied.  182 
 183 
Selection of the articles 184 
Titles were selected from first screening and abstracts of citations were reviewed by 185 
two independent reviewers (P.C. and D.C.G.) to identify all potentially relevant articles, 186 
which were subsequently fully evaluated by the same reviewers. Reference lists of 187 
relevant original and review articles were searched for additional reports. 188 
Disagreements were resolved by the opinion of a third party (L.C.P.). Entry criteria 189 
were randomized controlled trials evaluating the effect of aspirin administered at <11 190 
weeks’ of gestation in preventing preeclampsia and/or other hypertensive disorders in 191 
pregnancy as compared to placebo or no-treatment and outcome data available or 192 




Data extraction, construction of contingency tables and outcome measures 195 
The following information was extracted from the articles: author names, publication 196 
year, study design, method of randomization, blinding, type of comparison group, 197 
sample size in each group, gestational age at randomization, duration, dose and 198 
compliance of aspirin treatment. The primary end-point of this study was the rate of 199 
preeclampsia. Secondary end-points were the rates of gestational hypertension, any 200 
hypertensive disorder of pregnancy, preterm delivery at <37 weeks’ gestation and fetal 201 
growth restriction. Not all studies reported on the individual rates of preeclampsia and 202 
gestational hypertension, therefore, we divided outcomes as: 1) preeclampsia; 2) 203 
gestational hypertension (hypertension without proteinuria); and 3) any hypertensive 204 
disorder of pregnancy, which included either preeclampsia, HELLP (hemolysis, 205 
elevated liver enzymes, and a low platelet count) syndrome or gestational 206 
hypertension.  Data on primary and secondary end-points were documented in 207 
contingency tables. For all outcomes, analyses were carried out, as far as possible, 208 
on an intention-to-treat basis, i.e. we attempted to include all participants randomized 209 
to each group in the analyses. The denominator for each outcome in each trial was 210 
the number randomized minus any participants whose outcomes were missing or 211 
whose pregnancy did not reach 20 weeks. We contacted the authors directly when 212 
further clarification on their data, such as the precise gestational age for trial drug 213 
administration(74, 75) and the results according to singleton or multiple pregnancies,(40, 214 
50, 56, 76) were required. Only one author responded(40) and reported that for singleton 215 
pregnancies there were three and six cases of preeclampsia in the aspirin and placebo 216 
groups, respectively; and there were two cases of gestational hypertension in each 217 
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treatment group.  Statistical heterogeneity between the studies was evaluated with 218 
interaction terms between aspirin and trial.  219 
 220 
Quality evaluation 221 
 The quality of this review was validated with the Preferred Reporting Items for 222 
Systematic Reviews and Meta-Analyses (PRISMA) tool,(77) and the quality of each 223 
included trial was assessed by the Cochrane Handbook.(78) The methodological quality 224 
of the selected studies in terms of risk of bias and applicability was evaluated by three 225 
assessors (P.C., D.C.G., M.M.G.) using the Cochrane Risk of bias tool 2 (Rob 2).(79)  226 
 227 
Analyses 228 
Relative risks with 95% CI were calculated for each trial and pooled for global analysis 229 
as the effect measure. We assessed statistical heterogeneity in each meta-analysis 230 
using the Chi² statistics, I² and Tau². Heterogeneity was considered substantial if an I² 231 
was greater than 50% and either the Tau² was greater than zero, or there was a low 232 
P-value (<0.10) in the Chi² test for heterogeneity.(80, 81) In order to take into account 233 
clinical variability and/or heterogeneity between studies, random-effects meta-234 
analysis, weighted by the size of the trials, was performed to produce an overall 235 
summary on aspirin effect for each outcome.(82, 83) We have performed sensitivity 236 
analyses to examine statistical heterogeneity in two different ways, first, by omitting 237 
each study sequentially and assessing the effect estimate from remaining studies and 238 
second by calculating global estimates derived from fixed-effects model. Publication 239 
bias was not assessed due to the small number of included studies. We intended to 240 
perform meta-regression analyses to assess the effect of aspirin dosage for each 241 
outcome if the number of studies included for such purpose was at least ten.(78) 242 
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Statistical analysis was performed using Stata release 14.0 (StataCorp, College 243 





The literature search identified 766 citations: after removing duplicate articles (n=21) 249 
and articles that were not relevant (n=632), 113 articles were reviewed and eight 250 
randomized controlled trials on a combined total of 1,426 participants met the inclusion 251 
criteria (Figure 1). Table 1 demonstrated the characteristics of included studies. There 252 
were no studies with >15% drop out rate. 253 
 254 
Six out of the eight trials reported the effect of aspirin commenced at <11 weeks’ 255 
gestation on the rates of preeclampsia.(38, 40, 50, 56, 84, 85) Four out of the eight trials 256 
reported the effect of aspirin started at <11 weeks’ gestation on the rates of gestational 257 
hypertension.(40, 50, 84, 85) For any hypertensive disorder of pregnancy, there were eight 258 
trials reporting the effect of aspirin initiated at <11 weeks’ gestation.(38, 40, 50, 56, 76, 84-86) 259 
Lastly, six and five of the eight trials reported the effect of aspirin commenced at <11 260 
weeks’ gestation on the preterm delivery (40, 56, 76, 84-86) and fetal growth restriction,(38, 261 
40, 50, 56, 86) respectively. Seven of the included trials were considered to be good or 262 
unclear quality; one trial was considered at high risk of bias because some cases were 263 
excluded from final analysis due to loss to follow up. (Figure 2) The heterogeneity 264 




Low-dose aspirin initiated at <11 weeks’ gestation was associated with a non-267 
significant reduction in the risk of preeclampsia (RR 0.52; 95% CI: 0.23-1.17, 268 
P=0.115), gestational hypertension (RR 0.49; 95% CI: 0.20-1.21; P=0.121) and  any 269 
hypertensive disorders in pregnancy (RR 0.59; 95% CI 0.33-1.04, P=0.067). Early low-270 
dose aspirin was associated with a significant reduction in the risk of preterm delivery 271 
(RR 0.52; 95% CI: 0.27-0.97, p=0.040) but had no impact on the risk of fetal growth 272 
restriction (RR 1.10; 95% CI 0.58-2.07, P=0.775) (Figures 3-7, Table 2).  273 
 274 
Sensitivity analysis demonstrated that the overall results were similar in both direction 275 
and magnitude to the aforementioned results (Tables 2 and 3). Results derived from 276 
fixed-effects model analysis (Table 2) must only be interpreted for sensitivity analysis 277 
but not for treatment effect assessment because this type of analysis, which does not 278 
allow population parameters to vary across studies, leads to narrower confidence 279 
intervals and higher Type I error rates when there is any statistical or clinical variation 280 
between studies. By sequentially omitting studies, the pooled RR for preeclampsia 281 
ranged from 0.39 (95% CI: 0.16-1.00) to 0.68 (95% CI: 0.31-1.50). For gestational 282 
hypertension, the pooled RR ranged from 0.35 (95% CI: 0.09-1.37) to 0.69 (95% CI: 283 
0.27-1.76). The pooled RR for any hypertensive disorder during pregnancy ranged 284 
from 0.50 (95% CI:  0.24-1.04) to 0.77 (95% CI:  0.51-1.16), however, when the study 285 
by Kaandorp et al was omitted,(56) the estimated effect became significant (0.54; 95% 286 
CI: 0.30-0.98). For fetal growth restriction, the pooled RR ranged from 0.91 (95% CI: 287 
0.42-1.97) to 1.27 (95% CI: 0.65-2.47). For preterm birth, the results were more 288 
heterogeneous; only when Pattison et al ‘s study or Lambers et al’s study was omitted, 289 
the result remained significant. The pooled RR for preterm delivery ranged from 0.47 290 




All eight included studies provided information on the dosage of aspirin, ranging from 293 
50-100 mg daily. All except one study(38) used a dosage >75 mg/day. We did not 294 
perform meta-regression analysis since it required a large volume of individual studies 295 
to make meaningful interpretations from the data and should generally not be 296 




Principal findings of this study: The administration of low-dose aspirin at <11 301 
weeks’ gestation in women with a history of recurrent pregnancy loss, women who 302 
have undergone IVF or women with thrombophilia or antiphospholipid syndrome is 303 
associated with a non-significant decrease in the risk of preeclampsia, gestational 304 
hypertension, and any hypertensive disorder of pregnancy. Early low-dose aspirin 305 
might reduce the risk of preterm delivery; but there is no significant impact on the rate 306 
of fetal growth restriction. 307 
 308 
It has recently been demonstrated that aspirin given at 11-14 weeks’ gestation to 309 
women at risk reduces the frequency of preterm preeclampsia.(27) This approach for 310 
the prevention of preterm preeclampsia has now been endorsed by the International 311 
Federation of Gynecology and Obstetrics (FIGO).(23) However, the effect of aspirin on 312 
the enhancement of physiologic transformation in the spiral arteries of the placental 313 
bed is still questionable and unproven. Previous studies have demonstrated that 314 
uterine artery Doppler resistance index at 24-28 weeks’ gestation is not significantly 315 
different between women who receive and do not receive low-dose aspirin starting in 316 
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the first trimester of pregnancy,(10, 87-89) suggesting that the aspirin effect in preventing 317 
preeclampsia might be related to its action on platelets, rather than placental 318 
development. However, a recent in vitro study using trophoblast-derived cell line has 319 
demonstrated that the administration of low-dose aspirin can increase trophoblast 320 
placental growth factor secretion and restore perturbed cytokine levels (activated 321 
leukocyte cell adhesion molecule, chemokine (C-X-C motif) ligand (CXCL)-16, and 322 
Erb-B2 Receptor Tyrosine Kinase 3) induced by preeclampsia serum.(90) These 323 
findings indicate that aspirin might also modulate trophoblastic cell function. 324 
 325 
In relation to the treatment effect of preconception or early administration of aspirin in 326 
preventing placental associated complications, several hypotheses have been 327 
proposed. Low-dose aspirin, hypothetically, can improve endometrial growth and 328 
embryo implantation by: 1) reducing sub-endometrial contractility; 2) reducing 329 
endometrial inflammation by inhibiting cyclooxygenase and prostaglandin 330 
biosynthesis; and 3) increasing endometrial blood flow.(91, 92) Aspirin-mediated 331 
resolution of inflammation has been recently described as an alternative hypothesis. 332 
Aspirin is able to acetylate cyclooxygenase-2 to preserve and redirect its catalytic 333 
activity, leading to the production of 15(R)-hydroxyeicosatetraenoic acid, which is then 334 
converted by 5-lipoxygenase into aspirin-triggered lipoxins (ATLs).(93) ATLs act to 335 
resolve inflammation through their immune and angiogenic modulatory properties. In 336 
endothelial cells, ATLs can reduce the production of reactive oxygen species and 337 
differentially regulate neutrophil and monocyte chemotaxis. In immune cells, ATLs can 338 
inhibit NF-kappa B activity and pro-inflammatory cytokine production.(93) In addition, 339 
aspirin has been shown to improve trophoblast-endothelial cell integration in in vitro 340 
studies by inhibiting the effect of tumor necrosis factor-alpha via prostacyclin 341 
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production without any effects on anti-angiogenic, invasive (matrix metalloproteinase) 342 
or endothelial activation markers.(94, 95) However, in an in vivo study, aspirin has been 343 
shown to inhibit the expression of soluble fms-like tyrosine kinase (sFlt-1) in 344 
cytotrophoblast cultured cells, under a hypoxic state, from placentas of women with 345 
confirmed preeclampsia.(96) The result of the current meta-analysis indicates that the 346 
administration of low-dose aspirin at <11 weeks’ gestation is associated with a non-347 
significant decrease in the risk of preeclampsia, gestational hypertension, and any 348 
hypertensive disorder of pregnancy. However, when Kaandorp et al ’s study(56) is 349 
excluded, the effect of aspirin on the rate of any hypertensive disorder of pregnancy 350 
becomes significant (Table 3). It is probable that patient selection in this study has 351 
attributed to this finding. This study included women with ≥2 miscarriages without 352 
antiphospholipid syndrome, with or without inherited thrombophilia (rate of inherited 353 
thrombophilia ~16%). Thus far, the benefit of aspirin in the prevention of preeclampsia 354 
in women with thrombophilia is not established.(60) Of note, frequency of preeclampsia 355 
in this study was relatively low (aspirin group 3.3% (2/61) vs. placebo group 1.4% 356 
(1/70)).(56)  357 
 358 
Regarding preterm delivery, previous studies have demonstrated that a subset of 359 
pregnant women with spontaneous preterm birth has placental lesions associated with 360 
uteroplacental ischemia(97-102) and abnormal uterine artery Doppler.(103, 104)  Such 361 
findings are frequently observed in women with preeclampsia.(101, 105-116) Therefore, 362 
the underlying mechanisms responsible for the reduction in the rate of preterm delivery 363 
by preconception or early administration of aspirin might be similar to those proposed 364 
for preeclampsia. The results of the current meta-analysis have demonstrated that the 365 
administration of aspirin at <11 weeks’ gestation is associated with a significant 366 
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reduction in the risk of preterm birth. However, this observation becomes insignificant 367 
if some studies are excluded (Table 3), suggesting that, although there is an effect 368 
from aspirin, it is not robust enough. In Lambers et al’s study, 50% (2/4) and 100% 369 
(2/2) of women with preterm delivery in the aspirin and placebo groups, respectively, 370 
had twin pregnancies,(84) thus, this might account for the heterogeneity of the result. 371 
In the current meta-analysis, cases of preterm delivery include those resulting from 372 
spontaneous onset of labor as well as medical indications, such as preeclampsia, and 373 
therefore, in this instance, the reduction in the rate of preterm delivery is also likely to 374 
be mediated via a reduction in the rate of preeclampsia, which is one of the leading 375 
causes of medically indicated preterm delivery. 376 
 377 
Concerning the potential risks of aspirin usage during the very early stage of 378 
pregnancy, evidence from clinical trials and meta-analyses on low-dose aspirin in 379 
women with previous pregnancy loss has demonstrated that aspirin does not increase 380 
the risk of major bleeding, such as gastrointestinal bleeding, or major adverse events, 381 
such as congenital or neonatal abnormalities.(40, 50, 56, 60, 85, 86, 117) One study 382 
demonstrated that vaginal bleeding was more common in women receiving the 383 
treatment, (3.9% vs. 1.3%, p=0.004) but vaginal bleeding was not associated with an 384 
increased risk of miscarriage (13% vs. 12%, p=0.781).(117) The largest study included 385 
in this meta-analysis has also evaluated complications and safety of pre-conception 386 
low-dose aspirin in 1,228 American women.(76) The authors have demonstrated that 387 
the frequency of women with at least one possible aspirin-related symptom or at least 388 
one emergency care visit or maternal complication (except vaginal bleeding) during 389 
the trial is similar between treatment and placebo groups.(118) Although, vaginal 390 
bleeding is more commonly found in the low-dose aspirin group (22% compared with 391 
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17%, p=0.02), it is not associated with an increased risk of fetal and neonatal 392 
complications (stillbirth and neonatal death). The remaining seven studies have also 393 
reported that the administration of aspirin has not increased the risk of bleeding, 394 
postpartum hemorrhage or congenital anomalies.(38, 40, 50, 56, 84-86) In addition, a meta-395 
analysis of 22 studies has shown that maternal therapeutic use of aspirin in the first 396 
trimester is not associated with an overall increase in the risk of major congenital 397 
malformations, except for gastroschisis (OR 2.37, 95% CI: 1.44-3.88).(119) The latter 398 
finding has only been demonstrated in a case-control study (119) and it has not been 399 
confirmed in several large prospective cohort studies.(120-122) On the whole, the 400 
initiation of low-dose aspirin from the early stage of pregnancy is not associated with 401 
an increased risk of miscarriage or major congenital malformation. 402 
 403 
Comparison with previous studies on pre-conception or early administration of 404 
aspirin 405 
In addition to the randomized controlled trials included in the current meta-analysis, a 406 
number of observational studies, including three retrospective(123-125) and one 407 
prospective cohort studies,(126) have reported on the relationship between early 408 
administration of low-dose aspirin and the risk of preeclampsia. All studies included 409 
women with history of previous preeclampsia and/or other pregnancy complications 410 
such as preterm delivery or fetal death. The results are conflicting, in which three 411 
studies have reported that aspirin has no effect on the rate of preeclampsia,(123-125) 412 
while one study has demonstrated a reduction in the risk of the disorder (no treatment 413 
group 23.1% [3/13] vs. aspirin group 8.3% [1/12]).(126) 414 
 415 
Limitations of the study 416 
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A major limitation of this meta-analysis was that not all trials reported on the rate of 417 
preeclampsia and that some studies did not differentiate preeclampsia from 418 
gestational hypertension.(76, 86) The effect of compliance on the treatment effect size 419 
could not be evaluated as only four of the eight trials provided details of trial drug 420 
compliance. In addition, it was not possible to evaluate the effect of dose, exact timing, 421 
and indications of aspirin administration due to the small sample size of trials. With 422 
regard to duration of aspirin intake, all except one study administered aspirin until 36 423 
weeks’ gestation or delivery. (38, 40, 50, 56, 76, 85, 86) One study stopped aspirin at 12 weeks’ 424 
gestation.(84) The sensitivity analysis has demonstrated that the omission of this study 425 
does not alter the results (Table 3).   The most frequent indications for the initiation of 426 
preconception or early administration of aspirin were recurrent miscarriage (five 427 
studies; total subjects N=1,022),(38, 40, 56, 76, 86) followed by IVF treatment (two studies; 428 
total subjects N=122).(50, 84) Only one study evaluated the effect of early administration 429 
of aspirin on unselected nulliparous pregnant women.(85) Our results suggest that high 430 
risk women, in particular those with a history of recurrent miscarriage, might benefit 431 
from early administration of low-dose aspirin. All studies provided information about 432 
dosage of aspirin and all except one(38) used a dosage of more than 75 mg/day. 433 
Although it would be of interest to examine further the effect of aspirin dose in 434 
pregnancy outcome, the insufficient number of studies did not allow us to accurately 435 
perform meta-regression analysis. Lastly, two of the eight trials did not differentiate 436 
the results between singleton and multiple pregnancies but the number of multiple 437 
pregnancies included was very small (total n=6; 0.4%) and therefore we decided to 438 
include these trials in the meta-analysis.(56, 76) Although most studies (6/8) were 439 
considered as low risk of bias, (38, 40, 50, 56, 76, 86) one study was considered as having 440 
some concerns,(85) because of insufficient information to assess the quality of the 441 
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randomization and concealment process, and another study was considered as high 442 
risk of biased because some cases were excluded from final analysis due to loss to 443 
follow up.(84)  444 
 445 
Clinical implications of the study 446 
The key research question that has driven this meta-analysis is whether certain 447 
women, such as those with antiphospholipid syndrome or thrombophilia, would benefit 448 
from low-dose aspirin before pregnancy or during the very early stage of pregnancy 449 
as these women are considered to have the highest risk for the development of 450 
preterm preeclampsia and that waiting till 11-13 weeks’ gestation for screening and 451 
treatment is perceived to delay potential beneficial prophylaxis. 452 
 453 
Although, the primary objective for pre-conception or early administration of low-dose 454 
aspirin from the included randomized controlled trials was to improve the rate of live 455 
births in high risk pregnant women, the observations from our study suggest that such 456 
administration of aspirin was not associated with a reduction in the rates of 457 
preeclampsia, gestational hypertension any hypertensive disorder of pregnancy and 458 
fetal growth restriction.. However, it might be associated with a reduction in the rate of 459 
preterm delivery. The potential benefit might only be applicable to high risk women 460 
with a history of recurrent pregnancy loss or those who have undergone IVF treatment 461 
or those with thrombophilia or antiphospholipid syndrome. At present, there is no high 462 
quality evidence to support recommendation of preconception or early administration 463 
of low-dose aspirin for high risk women to prevent placenta-associated complications 464 
of pregnancy. Large prospective randomized controlled trials are needed to 465 
20 
 
substantiate our observations. Further work is also required to determine the optimal 466 
dosage, timing and duration of aspirin treatment.  467 
 468 
Conclusion 469 
This study has demonstrated that the administration of low-dose aspirin at <11 weeks’ 470 
gestation in high risk women does not reduce the risk of preeclampsia, gestational 471 
hypertension, any hypertensive disorder of pregnancy and fetal growth restriction. It 472 
might reduce the risk of preterm delivery.  473 
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Figure legend 482 
Figure 1: The flow diagram depicts the flow of information through the different phases 483 
of a the current meta-analysis 484 
Figure 2: Assessment of the risk of bias of included studies using the Cochrane Risk 485 
of bias tool 2.   486 
Figures 3-7: Forest plots of random-effects model in assessing early administration 487 
of aspirin and risk of pregnancy complications such as preeclampsia (Figure 3), 488 
gestational hypertension (Figure 4), any hypertensive disorder of pregnancy (Figure 489 
5), preterm birth <37 weeks’ gestation (Figure 6) and fetal growth restriction (Figure 490 
7) 491 
 492 
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